Want to see AU:OSL full AI Analyst Report?
OSL Stock Chart & Stats
AU$1.16
-AU$0.14(-11.97%)
At close: 4:00 PM EDT
AU$1.16
-AU$0.14(-11.97%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$1.64
Previous CloseN/A
Volume503.64K
Average Volume (3M)46.61K
Market Cap
AU$24.96M
Enterprise ValueAU$12.61M
Total Cash (Recent Filing)AU$6.48M
Total Debt (Recent Filing)AU$14.78K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding36,703,940
10 Day Avg. Volume17,538
30 Day Avg. Volume46,611
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.22
Price to Sales (P/S)9.54
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$4.40M
Bulls Say, Bears Say
Bulls Say
Targeted Oncology DeviceThe company has a focused interventional-oncology product aimed at a defined clinical use case. A device that complements standard treatment and is supported by clinical evidence, regulatory approvals, and commercialization efforts could build a durable pathway to adoption if execution continues.
Revenue GrowthAccelerating revenue indicates that OncoSil is making progress converting its product and commercialization efforts into reported sales. Although the base remains small, continued growth could improve operating leverage and provide a foundation for reducing losses over subsequent reporting periods.
Low Financial LeverageMinimal debt limits interest and refinancing pressure while preserving flexibility during the commercialization phase. This gives the company more time to invest in clinical, regulatory, and market-development activities without the additional fixed obligations associated with a heavily leveraged balance sheet.
Bears Say
Persistent UnprofitabilityNegative gross profit and substantial operating losses show that current revenue is not yet covering the economics of the business. Until scale, pricing, or cost control materially improves, the company remains exposed to prolonged losses and a slower path toward sustainable profitability.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is consuming cash rather than funding itself. Continued burn can constrain investment and increase reliance on external financing, particularly if operating performance does not improve enough to support the company’s ongoing activities.
Small Revenue BaseGrowth from a small starting base has not yet produced sufficient operating scale to offset the company’s cost structure. The investment case therefore depends heavily on sustained commercial expansion and tighter cost control, leaving execution risk elevated over the next several quarters.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.37 and its highest was AU$1.64 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$24.96M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 121 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Aug 28, 2026. The company reported -AU$0.236 earnings per share for the quarter.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 36,703,940 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.236 in its last earnings report. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 86%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.32%
12-Months-Change
Fundamentals
Return on Equity
-245.90%
Trailing 12-Months
Asset Growth
44.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Technical Analysis
Polynovo
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―